Analysis of expression and prognostic value of CXC subfamily receptor 4 in esophageal squamous cell carcinoma
Objective To explore the expression of CXC subfamily receptor 4(CXCR4)in esophageal squamous cell carcinoma(ESCC)and its correlation with clinicopathological features and prognosis of ESCC patients.Methods This study was a retrospective cohort study.A total of 107 ESCC patients underwent radical esophagectomy for esophageal cancer in the First Affiliated Hospital of Bengbu Medical College from January to December 2018 were selected as the study group,and the adjacent tissues of 21 patients among them were selected as the control group.The expression of CXCR4 in the two groups was determined by immunohistochemical stain,and the clinical medical records of 107 ESCC patients were analyzed to study the relationship between CXCR4 expression and clinicopathological features and prognosis of the patients.Results The positive expression rate of CXCR4 in the study group was higher than that in the control group,and the difference was statistically significant(P＜0.05).There were statistically significant differences in CXCR4 expression levels in cancer tissues of ESCC patients with different ages,degrees of differentiation,depth of invasion,and lymph node metastasis(P＜0.05).Kaplan-Meier survival curve analysis showed that the overall survival and disease-free survival of patients with CXCR4 positive expression were lower than those with negative expression,and the differences were statistically significant(P＜0.05).Cox regression model analysis showed that the depth of tumor invasion,degree of differentiation,lymph node metastasis,and CXCR4 expression level were independent influencing factors for overall survival and disease-free survival in ESCC patients(P＜0.05).Conclusion The positive expression rate of CXCR4 in cancer tissues of ESCC patients increased,and the high expression of CXCR4 may promote ESCC invasion of esophagus and lymph node metastasis.The high expression of CXCR4 in ESCC may be associated with poor patient outcomes.
NETL
NSTL
万方数据
